632 related articles for article (PubMed ID: 29384795)
1. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
[TBL] [Abstract][Full Text] [Related]
2. Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease.
Mueller S; Nahon P; Rausch V; Peccerella T; Silva I; Yagmur E; Straub BK; Lackner C; Seitz HK; Rufat P; Sutton A; Bantel H; Longerich T
Hepatology; 2017 Jul; 66(1):96-107. PubMed ID: 28170108
[TBL] [Abstract][Full Text] [Related]
3. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
5. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease.
Ergelen R; Akyuz U; Aydin Y; Eren F; Yilmaz Y
Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):667-71. PubMed ID: 25923941
[TBL] [Abstract][Full Text] [Related]
6. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.
Younossi ZM; Page S; Rafiq N; Birerdinc A; Stepanova M; Hossain N; Afendy A; Younoszai Z; Goodman Z; Baranova A
Obes Surg; 2011 Apr; 21(4):431-9. PubMed ID: 20532833
[TBL] [Abstract][Full Text] [Related]
7. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
Pimentel CF; Jiang ZG; Otsubo T; Feldbrügge L; Challies TL; Nasser I; Robson S; Afdhal N; Lai M
Dig Dis Sci; 2016 Mar; 61(3):905-12. PubMed ID: 26462489
[TBL] [Abstract][Full Text] [Related]
8. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
[TBL] [Abstract][Full Text] [Related]
9. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
Malik R; Chang M; Bhaskar K; Nasser I; Curry M; Schuppan D; Byrnes V; Afdhal N
J Gastroenterol Hepatol; 2009 Apr; 24(4):564-8. PubMed ID: 19378390
[TBL] [Abstract][Full Text] [Related]
10. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
Tanwar S; Trembling PM; Guha IN; Parkes J; Kaye P; Burt AD; Ryder SD; Aithal GP; Day CP; Rosenberg WM
Hepatology; 2013 Jan; 57(1):103-11. PubMed ID: 22930399
[TBL] [Abstract][Full Text] [Related]
11. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation.
Walenbergh SM; Houben T; Hendrikx T; Jeurissen ML; van Gorp PJ; Vreugdenhil AC; Adriaanse MP; Buurman WA; Hofker MH; Mosca A; Lindsey PJ; Alisi A; Liccardo D; Panera N; Koek GH; Nobili V; Shiri-Sverdlov R
Am J Gastroenterol; 2015 Mar; 110(3):462-70. PubMed ID: 25732418
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
[TBL] [Abstract][Full Text] [Related]
14. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis.
Joka D; Wahl K; Moeller S; Schlue J; Vaske B; Bahr MJ; Manns MP; Schulze-Osthoff K; Bantel H
Hepatology; 2012 Feb; 55(2):455-64. PubMed ID: 21993925
[TBL] [Abstract][Full Text] [Related]
15. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease.
Kawanaka M; Nishino K; Nakamura J; Urata N; Oka T; Goto D; Suehiro M; Kawamoto H; Yamada G
Ann Hepatol; 2015; 14(6):837-44. PubMed ID: 26436355
[TBL] [Abstract][Full Text] [Related]
16. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
Castera L
Semin Liver Dis; 2015 Aug; 35(3):291-303. PubMed ID: 26378645
[TBL] [Abstract][Full Text] [Related]
18. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
19. The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease.
Liang J; Han T; Gao YT; Jing L; Ma Z
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(21):4123-9. PubMed ID: 26592838
[TBL] [Abstract][Full Text] [Related]
20. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
